Falsely elevated serum salicylate concentration secondary to hyperlipidemia

Paul Mark HinckleyUtah Poison Control Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA; Correspondence[email protected]

B. Zane HorowitzMedical Director, Oregon-Alaska Poison Center, Oregon Health Science University, Portland, OR, USA

Barbara I. CrouchUtah Poison Control Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA;

References

Biary R, Kremer A, Goldfarb DS, et al. Falsely elevated salicylate concentration in a patient with hypertriglyceridemia. Toxicol Commun. 2018;2(1):1–2. DOI:10.1080/24734306.2017.1412566.
Google Scholar
You K, Bittikofer JA. Quantification of salicylate in serum by use of salicylate hydroxylase. Clin Chem. 1984;30(9):1549.
Google Scholar
Baer DM, Paulson RA. The effect of hyperlipidemia on therapeutic drug assays. Ther Drug Monit. 1987;9(1):72–77.
Google Scholar
Kroll MH. Evaluating interference caused by lipemia. Clin Chem. 2004;50(11):1968–1969. DOI:10.1373/clinchem.2004.038075.
PubMed Web of Science ®Google Scholar
Meany D, Schowinsky J, Clarke W. Effects of hemolysis and lipemia on the COBAS salicylate and acetaminophen assays compared to GDS assays. Clin Biochem. 2008;41(18):1486–1488. doi: 10.1016/j.clinbiochem.2008.09.111.
Google Scholar
Kroll MH, Elin RJ. Interference with clinical laboratory analyses. Clin Chem. 1994;40(11 Pt 1):1996–2005.
PubMed Web of Science ®Google Scholar
Charlton NP, Lawrence DT, Wallace KL. Falsely elevated salicylate levels. J Med Toxicol. 2008;4(4):310–311. PubMed PMID: 19031386; PubMed Central PMCID: PMCPMC3550119.
Google Scholar